Azzet reports on three ASX stocks trading double-digits higher after notable trading updates today.
Drone Shield rallies on news of new R&D ramp-up
Shares in Drone Shield (ASX: DRO) were up 10.47% at the open after the counter drone technology company revealed plans to invest $13 million to triple the size of its current R&D facility.
Due to open late in 2025, the company has taken out a multi-year lease and fit-out at Sydney's Alexandria which will become a brand new 3,000 sqm production facility.
While there is no requirement for heavy machinery and similar capital expenditure investment, the new facility includes advanced in-house production, testing and warehousing capabilities.
It’s hoped that a ramp-up of its R&D capabilities will further the company’s plans to expand its own annual production capacity to $900 million by mid-2026.
With a combined total annual manufacturing capacity of $2.4 billion by the end of 2026, the company is planning to target a $2.34 billion and rapidly growing global sales pipeline including Europe, its fastest-growing export market.
Today’s announcement follows some major wins for the company this year, including:
- $61.6 million European contract in June – it's the single biggest single order to date.
- $9.7 million Latin American contract
- $11.7 million Five-Eyes R&D contract.
To reflect the broader increase in military spending across the EU region, DroneShield has also announced its significant expansion into Europe.
The company is also planning to establish a European Centre of Excellence with manufacturing and production facilities, to support the continent’s domestic defence programs.
Commenting on today’s update DroneShield’s CEO Oleg Vornik told the market the company was stepping up to meet the demand for modern defence capabilities by investing in state-of-the-art facilities here and abroad.
“Our new facility in Alexandria will epitomise the value Australian engineering can bring to a changing geopolitical landscape,” he said.
DroneShield's share price has been on a tear in recent months, having jumped over 300% since the start of the year.
At an investor presentation in June the company told the market it had won $131.7 million in contracts year-to-date.
At 20 June the stock had a cash balance of $198.1 million and no debt.
Drone Shield has a market cap of around $2.6 billion; the share price has been up 74% in the last month.
The stock appears to be in a strong bullish trend confirmed by multiple indicators. Specifically, the 5-day moving average of the stock price is above the 20 and 50-day moving averages.
Consensus is Strong Buy.
Hansen Technologies jumps after upgrading FY25 earnings
Shares in Hansen Technologies (ASX: HSN) were up around 12% at the open after the global provider of software and services guided to underlying earnings for FY25 of between $110-112 million, up from $92-101 million.
While operating revenue is expected to contract to between $391 million to $393 million, down from the previous $398 million to $405 million, the earnings upgrade is being attributed to a turnaround in the Powercloud business, plus improved operating efficiencies and disciplined cost management.
However, management noted that while the revenue miss is due primarily to project timings - resulting in a modest adjustment to the previous revenue guidance - it should show up in FY26.
Meanwhile, cash earnings are now expected to come in between $92 million and $94 million, up from the previous $76 million to $85 million.
Management told the market today that industry tailwinds from both Hansen verticals are driving increased demand for the group’s products and services globally.
“The Company has a solid pipeline of committed business and remains optimistic about its growth potential beyond FY25,” management said.
Recent customer wins include:
• A four-year agreement with Vattenfall to implement the Hansen CIS in Finland for a TCV of $5.5m.
• An agreement with a Nordic B2B energy retailer Å Entelios to deploy Hansen CIS in support of its expansion into the Danish market.
• A transformative $50 million five-year agreement with VMO2, a JV between Telefónica and Liberty Global, announced to the market on 3 February 2025.
• A strategic five-year agreement with one of the largest renewable energy portfolios in the US, for an estimated contract value of $16 million.
• Multiple new agreements with a combined TCV of over $5 million and increased annual recurring revenue by $1.4 million for various modules of the automated Hansen Trade platform.
New customers include Aneo, Modity, World Kinect, Ingrid Capacity and Å Entelios. Regions include Finland, Sweden and Hansen’s first ever deployments of Hansen Trade into Norway, Denmark and The Netherlands.
At the half year the company today announced a 6.1% increase in operating revenue and announced a $50 million five-year master agreement with VMO2, a communications joint venture between Telefónica and Liberty Global in the UK which has contributed $15 million of licence fee revenue in 2H25.
The company plans to release its full-year results on Wednesday 20 August 2025.
Hansen’s revenue is diverse across geography, currency, product and industry with no single customer making up more than 8% of revenue. Customer churn rates remain consistently low, and the customer base is largely tier 1 and 2.
Hansen Technologies has a market cap of around $1.1 billion; the share price is up 21% year to date and flat year to date.
The stock is still trading around 15% lower than its 5-year high of $6.32.
The stock’s shares appear to be in a near-term downtrend confirmed by its 20-day moving average.
Consensus is Strong Buy.
Compumedics leaps on robust market update
Shares in Compumedics (ASX: CMP) were up around 24% at the open after the medical device smallcap told the market that FY25 was a watershed year marked by record sales orders and a return to profitability.
In addition to strong growth in the U.S. and its SaaS segments - setting a solid foundation for FY26 – the market has also responded favourably to revelations that the company is positioned to scale into a more focused, higher-margin business model underpinned by recurring revenues, new product launches, and meaningful traction in the U.S. and across its connected platforms.
Within today’s update, executive chairman David Burton described the FY25 result – with earnings increasing around $3 million - as a step-change underway at Compumedics.
“FY26 will see us scale into a more focused, cash-generative global business underpinned by recurring revenues from Somfit and clinical innovation, with MEG deliveries and growing demand in China providing further upside,” he said.
As well as reaffirming its FY26 guidance - projecting revenue of at least $70 million and earnings of around $9 million, the company expects its SaaS and connected platforms (Somfit + Nexus 360 segment) to contribute over 20% of group revenue, delivering high margins and scalability.
The launch of the disposable Somfit (Somfit D) in the U.S. is expected to increase penetration of the home sleep test market.
Three MEG (Magnetoencephalography) systems are on track for FY26 revenue, with paediatric market expansion increasing the MEG opportunity to approximately $120 million.
MEG system deliveries refer to the process of shipping and installing these advanced brain imaging systems, often to research institutions or hospitals, after they are purchased.
Best known for its commercialisation of diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications, the company delivered the following FY25 results:
• Sales orders reached a record $63.4 million; a 22% increase compared to FY24.
• The Sleep & Neurology segment saw a 39% rise in orders, reaching $53.0 million, driven by substantial growth in US Sleep Diagnostics, which increased by 102% to $23.5 million.
• Somfit + Nexus 360 SaaS orders also experienced significant growth, rising by 49% to $6.7 million, with US Somfit sales orders increasing by 675% from $0.4 million to $3.1 million.
• MEG orders totalled $5.9 million, with three systems in progress for revenue recognition in FY26, valued at approximately $15 million.
• The Sleep & Neurology segment contributed $46.3 million, a 16% increase.
• The Somfit + Nexus 360 SaaS segment generated $6.0 million in revenue, a 41% rise.
Compumedics has a market cap of $60 million; the share price is up 5% in one year and up 20% in the last week.
The stock's shares appear to be in a long-term bearish trend confirmed by multiple indicators.
Consensus does not cover this stock.
This article does not constitute financial or product advice. You should consider independent advice before making financial decisions.
